Associate Director, CAR T CMC/TCT Program Management - CTDO - Bristol-Myers Squibb
Warren, New Jersey
Associate Director Project Management - Project Leadership
August 2015 to September 2017
Celgene Cellular Therapeutics
Associate Director - Tissue Therapeutics Product Research and Development
November 2014 to August 2015
Celgene Cellular Therapeutics
Principal Scientist - Tissue Therapeutics Research and Development
November 2013 to November 2014
Celgene Cellular Therapeutics
Senior Scientist -Tissue Therapeutics Research and Development
January 2011 to November 2013
January 2009 to December 2010
Thomas Jefferson University, Translational Medicine
January 2007 to June 2009
Thomas Jefferson University
February 2002 to January 2007
Associate Director Program Managment - Cell Therapy Development and Operations
Responsibilities Include:- Managing early phase drug development programs- Serving as secretary of Early Development Advisory Committee for the different franchises Responsibilities Include:- Managing early phase drug development programs- Serving as secretary of Early Development Advisory Committee for the different franchises
What company does Raihana Zaka work for?
Raihana Zaka works for Celgene Corporation
What is Raihana Zaka's role at Celgene Corporation?
Raihana Zaka is Associate Director Project Management - Project Leadership
What industry does Raihana Zaka work in?
Raihana Zaka works in the Pharmaceuticals industry.
Associate Director Project Management - Project Leadership @ Celgene Corporation Responsibilities Include:- Managing early phase drug development programs- Serving as secretary of Early Development Advisory Committee for the different franchises From August 2015 to September 2017 (2 years 2 months) Associate Director - Tissue Therapeutics Product Research and Development @ Celgene Cellular Therapeutics Responsibilities include: • Leading transfer of analytical methods from R&D to GMP • Co-leading analytical support for GMP process validation and for USP Monograph with QC analytical lead• Coordinating and co-leading product scientific branding in support of commercial partner • Representing Tissue Therapeutics R&D in selected key conferences, workshops, and internal and external meetings From November 2014 to August 2015 (10 months) Warren, NJ.Principal Scientist - Tissue Therapeutics Research and Development @ Celgene Cellular Therapeutics Responsibilities included: Lead and managing R&D analytics teamMeasurable results:• Led in-house analytics, including the development and qualification of assay for biochemical characterization of candidate biomaterial products• Responsible for identifying external organizations/CROs and establishing contracts for completion of assay validations • Designed safety and biocompatibility study plans and protocols in accordance with FDA guidelines for medical devices • Managed and coordinated execution, by CROs, of assay validations and safety studies to GLP standards • Responsible for coordinating material supply for pre-clinical/biocompatibility studies and for providing product certificates• Defined product release assays• Actively participated in pre-market notification submission From November 2013 to November 2014 (1 year 1 month) Warren, NJSenior Scientist -Tissue Therapeutics Research and Development @ Celgene Cellular Therapeutics Responsibilities include: Project LeaderMeasurable results:• Led/executed proof of concept-related projects including cell-tissue scaffold interactions• Developed in vitro assays for biochemical characterization of candidate tissue-based products• Developed method for surface modification/enhancement of biomaterials• Established key academic collaborations • Led exploratory efficacy and safety in vivo studies, executed with academic collaborations and CROs From January 2011 to November 2013 (2 years 11 months) Warren, NJ.Research Associate @ TJU Signaling pathways involved in proliferation and differentiation mechanisms of adult cardiac stem cells. · Engineering Lentiviral constructs - titrating lentivirus - optimizing isolation and expansion of adult mouse cardiac stem cells. From January 2009 to December 2010 (2 years) Research Associate @ Thomas Jefferson University, Translational Medicine Responsible for 2 parallel projects on Ank gene, involved in Chondrocalcinosis (familial form of arthritis), characterized by deposition of Calcium PyroPhospahte Dihydrate or CPPD crystals in cartilage (physiologically non-calcifying tissue).1.Study of the effect of O2 tension on Ank gene expression:• analysis of Ank transcript levels by real time RT-PCR under various O2 tensions• discovery of the existence of interaction between a specific O2 responsive transcription factor and Ank promoter by ChIP • study of Ank promoter activity using a reporter systemFindings: Ank gene is responsive to O2 with repression of its activity at low O2 tension. Biological relevance: inhibition of crystal formation near zones rich in O2 (cartillage, arteries).2.Study of transmembrane protein, ANK, topology: - development of custom antibodies recognizing specific epitops by Immunocytochemical (fluorescent, confocal microscopy) and FACS analysis.These 2 projects were finalized in manuscripts and poster presentations. From January 2007 to June 2009 (2 years 6 months) Postdoctoral fellow @ Thomas Jefferson University Mutations in Ank gene are responsible for familial CPPDD, affecting patients in their 20s, with late stage osteoarthritis symptoms. Ank codes for a transmembrane protein, regulating inorganic pyrophosphate (PPi) transport. To clarify how these mutations perturbates PPi metabolism, responsible for CPPD deposition, I successfully accomplished these tasks in an in vitro system:•Creation of mutants by site directed mutagenesis•Study of gene expression during chondrogenesis by classic & microarray based real time rt-PCR •Design & creation of constructs for transient transfection & stable viral transduction •Selection of clonal population by real time RT-PCR•Development of a sensitive extra & intracellular PPi assayThis work has resulted in 9 presentations & abstracts and 1 peer review publication showing that not all mutations in Ank cause a gain of ANK protein function. From February 2002 to January 2007 (5 years) Associate Director Program Managment - Cell Therapy Development and Operations @ Bristol-Myers Squibb Responsibilities include:- Managing TCT and Lifecycle Managements Teams in the cell therapy (CAR T) space- Leading integration of CMC and Manufacturing activities Summit, NJ
Extraversion (E), Sensing (S), Feeling (F), Judging (J)
2 year(s), 4 month(s)
There's 100% chance that Raihana Zaka is seeking for new opportunities
Enjoy unlimited access and discover candidates outside of LinkedIn
Trusted by 400K users from
76% of Fortune 500 companies
The most accurate data ever
Hire Anyone, Anywhere
with ContactOut today
Making remote or global hires? We can help.
No credit card required